Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2013 15:23 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012

PHILADELPHIA, March 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the fiscal year ended December 31, 2012. The net loss for 2012's twelve month...
March 04, 2013 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina

PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
February 04, 2013 19:35 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and...
December 21, 2012 14:57 ET | Source: Hemispherx Biopharma, Inc.

FDA Advisory Committee Makes Recommendations on Ampligen (R) for Chronic Fatigue Syndrome

PHILADELPHIA, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee...
November 02, 2012 15:11 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2012

PHILADELPHIA, Nov. 2, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended September 30, 2012. The net comprehensive loss for the period...
October 22, 2012 08:49 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012

PHILADELPHIA, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the U.S. Food and Drug Administration ("FDA") has...
October 01, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Files for Treatment Expansion in Argentina for Alferon N Injection(R) for Hepatitis C

PHILADELPHIA, Oct. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced that the Company has filed with ANMAT (Administracion Nacional de...
September 24, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen(R) for Chronic Fatigue Syndrome

PHILADELPHIA, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the U.S. Food and Drug Administration ("FDA") has...
September 19, 2012 15:44 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Reports on Annual Stockholder Meeting

PHILADELPHIA, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it held its 2012 Annual Meeting of Stockholders on September 18, 2012. Final voting results will be...
September 06, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma to Present at the Rodman and Renshaw 14th Annual Healthcare Conference

PHILADELPHIA, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 14th Annual...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right